Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LBL-034 in Relapsed/Refractory Multiple Myeloma
NCT06049290Phase 2Recruiting
- Sponsor
- Leads Biolabs
- Start
- Oct 2023
- Primary completion
- Oct 2026
- Modality
- Bispecific Antibodies, T-cell Engagers
- Countries
- 1
01
Overview
A Phase 2 trial of LBL-034 in multiple myeloma (MM), plasma cell leukemia (PCL), sponsored by Leads Biolabs. Started Oct 2023; status: recruiting.
02
Drugs
LBL-034
03
Conditions
multiple myeloma (MM)plasma cell leukemia (PCL)
Beyond the preview
Go deeper on NCT06049290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06049290.